Choline and Docosahexaenoic Acid: study protocols
16 study groups took Choline together with Docosahexaenoic Acid. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Choline
15 study groups in 8 studies say how much Choline participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mg to 500 mg, 40% of 15 study groups.
| Daily dose | Study groups |
|---|---|
| 10 mg to 25 mg | 2 |
| 25 mg to 50 mg | 0 |
| 50 mg to 100 mg | 1 |
| 100 mg to 250 mg | 1 |
| 250 mg to 500 mg | 6 |
| 500 mg to 1 g | 5 |
Dose per serving from research: Docosahexaenoic Acid
11 study groups in 7 studies say how much Docosahexaenoic Acid participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 100 mg to 250 mg, 64% of 11 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mg to 250 mg | 7 |
| 250 mg to 500 mg | 1 |
| 500 mg to 1 g | 0 |
| 1 g to 2.5 g | 3 |
Commonly used together
9 of 16 study groups took Choline and Docosahexaenoic Acid with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Folic Acid | 5 |
| Vitamin B12 | 4 |
| Omega-3 Fatty Acids | 3 |
16 study groups
| Study | ||||
|---|---|---|---|---|
| Benefits of Krill Oil Supplementation During Alternate-Day Fasting in Adults With Overweight and Obesity: A Randomized Trial 2025 · KO group · Healthy adults aged 25–65 with BMI >25 kg/m² and overweight or obesity; 25 women and 16 men enrolled | 156 mg | 188 mg | 12 weeks | 21 |
| Genetic Variants in One-Carbon Metabolism and Their Effects on DHA Biomarkers in Pregnant Women: A Post-Hoc Analysis 2022 · intervention group · Healthy pregnant women aged 21–40 years, BMI <32, enrolled at 12–16 gestational weeks | 550 mg | 200 mg | — | 15 |
| Reproductive state and choline intake influence enrichment of plasma lysophosphatidylcholine-DHA: a post hoc analysis of a controlled feeding trial 2019 · 930 mg choline per day group · Healthy non-pregnant, third-trimester pregnant, and lactating women; reproductive groups were included in the analysis | 550 mg | 200 mg | 12 weeks | — |
| Prenatal choline supplementation improves biomarkers of maternal docosahexaenoic acid (DHA) status among pregnant participants consuming supplemental DHA: a randomized controlled trial 2022 · Control group · Pregnant participants aged 21–40 years, enrolled at 12–16 weeks’ gestation, without the specified health conditions or pregnancy complications | 25 mg | 200 mg | 169 days | 15 |
| Genetic Variants in One-Carbon Metabolism and Their Effects on DHA Biomarkers in Pregnant Women: A Post-Hoc Analysis 2022 · control group · Healthy pregnant women aged 21–40 years, BMI <32, enrolled at 12–16 gestational weeks | 25 mg | 200 mg | — | 15 |
| Combined choline and DHA supplementation: a randomized controlled trial 2020 · combined choline and DHA supplementation · Preterm infants born before 32 weeks postmenstrual age | 30 mg/kg | 60 mg/kg | 10 days | — |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active group (RCT1, RCT2 and RCT3) · Men and women aged 50 years or older with mild or mild-to-moderate Alzheimer's disease; RCT3 participants were on stable approved Alzheimer's medication, while RCT1 and RCT2 participants were drug-free for Alzheimer's medication. | 400 mg | 1.2 g | 24 weeks | 501 |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active product during open-label extension (OLE) · Men and women aged 50 years or older with mild Alzheimer's disease who completed RCT2. | 400 mg | 1.2 g | 24 weeks | 201 |
| Prenatal choline supplementation improves biomarkers of maternal docosahexaenoic acid (DHA) status among pregnant participants consuming supplemental DHA: a randomized controlled trial 2022 · Intervention group · Pregnant participants aged 21–40 years, enrolled at 12–16 weeks’ gestation, without the specified health conditions or pregnancy complications | 550 mg | 200 mg | 171 days | 15 |
| Choline intake influences phosphatidylcholine DHA enrichment in nonpregnant women but not in pregnant women in the third trimester 2013 · Pregnant women, 480 mg choline/day · Pregnant women in the third trimester | 480 mg | — | 12 weeks | — |
| Choline intake influences phosphatidylcholine DHA enrichment in nonpregnant women but not in pregnant women in the third trimester 2013 · Pregnant women, 930 mg choline/day · Pregnant women in the third trimester | 930 mg | — | 12 weeks | — |
| Choline intake influences phosphatidylcholine DHA enrichment in nonpregnant women but not in pregnant women in the third trimester 2013 · Nonpregnant women, 480 mg choline/day · Nonpregnant women | 480 mg | — | 12 weeks | — |
| Choline intake influences phosphatidylcholine DHA enrichment in nonpregnant women but not in pregnant women in the third trimester 2013 · Nonpregnant women, 930 mg choline/day · Nonpregnant women | 930 mg | — | 12 weeks | — |
| Use of a Micronutrient Cocktail to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adults with Obesity: A Randomized, Double-Blinded Pilot Clinical Trial 2024 · intervention group · Adults aged 18–70 with obesity and dyslipidemia | 500 mg | 280 mg | 90 days | 105 |
| The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial 2017 · Test product (Souvenaid/Fortasyn Connect) · Adults aged 50 years or older with mild probable or possible Alzheimer’s disease | 400 mg | 1.2 g | 4 weeks | 16 |
| Reproductive state and choline intake influence enrichment of plasma lysophosphatidylcholine-DHA: a post hoc analysis of a controlled feeding trial 2019 · 480 mg choline per day group · Healthy non-pregnant, third-trimester pregnant, and lactating women; reproductive groups were included in the analysis | 100 mg | 200 mg | 12 weeks | — |